Vascular inflammation and cardiovascular disease (CVD) are the leading causes of morbidity and mortality in the diabetic population, and are thus a major public health issue [ 1 ] [ 2 ]. Epidemiological case-control studies suggest an inverse association between chromium (Cr3+) levels in toenails and the risk of myocardial infarction in the general population [ 3 ]. Similarly, a recent report within the Health Professionals Follow-up Study has found lower levels of toenail chromium among men with diabetes and CVD compared to healthy control subjects [ 4 ]. Chromium supplementation is popular in some countries [ 4 ]. The molecular mechanisms by which Cr3+ produces its effects on insulin sensitivity and vascular inflammation have not yet been studied. Several pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNFα) and interleukin (IL)-6, play a significant role in the development of vascular complications in many models of inflammation, including diabetes [ 2 ]. No studies have examined the effect of chromium on secretion of pro-inflammatory cytokines in any human cell. This is the first study to report that Cr3+ supplementation can prevent TNFα and IL-6 secretion in exposed peripheral blood mononuclear cells (PBMC) exposed to high glucose concentrations and isolated from the blood of human volunteers. This provides evidence for a novel molecular mechanism by which Cr3+ supplementation may protect diabetic patients from vascular inflammation.